Cardiac adverse drug reactions to COVID-19 vaccines. A cross-sectional study based on the Europe-wide data
European Heart Journal - Cardiovascular Pharmacotherapy · 2024
DOI: 10.1093/ehjcvp/pvae063 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift European Heart Journal - Cardiovascular Pharmacotherapy, 2024. Verfasst von Wojciech Nazar und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Medical University of Gdańsk, Marii Skłodowskiej-Curie 3a, 80-210 Gdańsk, Poland. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
Aims
We aimed to analyse serious cardiac adverse drug reactions to COVID-19 vaccines from the Europe-wide EudraVigilance database. Methods and results In this retrospective, cross-sectional study, the EudraVigilance database was searched to identify suspected serious cardiac post-vaccination adverse drug reactions to COVID-19 vaccines. This data was coupled with the number of total vaccine doses administered in the European Economic Area for Comirnaty (Pfizer BioNTech), Spikevax (Moderna), Vaxzevria (AstraZeneca), Jcovden (Janssen), Nuvaxovid (Novavax), products, available from the European Centre for Disease Prevention and Control ‘Vaccine Tracker’ database. The analysis included 772 228 309 administered doses of eligible vaccines from the ‘Vaccine Tracker’ database and 86 051 eligible records of cardiac adverse drug reactions from the EudraVigilance database. The frequency of most of the investigated adverse drug reactions was very rare (<1/10 000 i.e. <100/1 000 000 doses). The lowest risk of any serious cardiac adverse drug reactions was noticed for vaccination with Comirnaty (135.5 per million doses), while Spikevax, Jcovden, Vaxzevria, and Nuvaxovid were characterized by higher risk (respectively, 140.9, 194.8, 313.6, and 1065.2 per million doses). The most common complications of vaccinations included syncope, arrhythmia, tachycardia, palpitations, angina pectoris, hypertension, myocarditis, thrombosis, and pulmonary embolism.
Conclusion
The risk of serious cardiac adverse drug reactions to COVID-19 vaccines is low and the benefit of active immunization against that disease seems to outweigh the potential risk of serious post-vaccination cardiac adverse drug reactions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Medical University of Gdańsk, Marii Skłodowskiej-Curie 3a, 80-210 Gdańsk, Poland.
- Department of Allergology, Faculty of Medicine, Medical University of Gdańsk, Smoluchowskiego 17, 80-214 Gdańsk, Poland.
- Department of Cardiology and Electrotherapy, Faculty of Medicine, Medical University of Gdańsk, Smoluchowskiego 17, 80-214 Gdańsk, Poland.
ORCID-Profile: Wojciech Nazar, Jan Romantowski, Marek Niedoszytko, Ludmiła Daniłowicz-Szymanowicz
Zitieren
APA
Nazar, W., Romantowski, J., Niedoszytko, M., & Daniłowicz-Szymanowicz, L. (2024). Cardiac adverse drug reactions to COVID-19 vaccines. A cross-sectional study based on the Europe-wide data. European Heart Journal - Cardiovascular Pharmacotherapy. https://doi.org/10.1093/ehjcvp/pvae063
Vancouver
Nazar W, Romantowski J, Niedoszytko M, Daniłowicz-Szymanowicz L. Cardiac adverse drug reactions to COVID-19 vaccines. A cross-sectional study based on the Europe-wide data. European Heart Journal - Cardiovascular Pharmacotherapy. 2024. doi:10.1093/ehjcvp/pvae063
BibTeX
@article{Nazar2024,
author = {Nazar, Wojciech and Romantowski, Jan and Niedoszytko, Marek and Daniłowicz-Szymanowicz, Ludmiła},
title = {Cardiac adverse drug reactions to COVID-19 vaccines. A cross-sectional study based on the Europe-wide data},
journal = {European Heart Journal - Cardiovascular Pharmacotherapy},
year = {2024},
doi = {10.1093/ehjcvp/pvae063}
}
EUVIMED